NASDAQ: ATHEAlterity Therapeutics Ltd Stock
$4.11-0.04 (-0.96%)
Updated Jun 11, 2026
ATHE Price
$4.11
Fair Value Price
N/A
Market Cap
$89.40M
52 Week Low
$2.66
52 Week High
$7.00
P/E
-6.9x
P/B
2.32x
P/S
7.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.27M
Earnings
-$9.79M
Gross Margin
100%
Operating Margin
-163.6%
Profit Margin
-165.1%
Debt to Equity
0.05
Operating Cash Flow
-$9M
Beta
0.66
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATHE Overview
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATHE's potential to beat the market
- ATHE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATHE
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important ATHE news, forecast changes, insider trades & much more!
ATHE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATHE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATHE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATHE is good value based on its book value relative to its share price (2.32x), compared to the US Biotechnology industry average (4.83x)
P/B vs Industry Valuation
ATHE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATHE due diligence checks available for Premium users.
Valuation
ATHE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.9x
Industry
17.66x
Market
13.95x
ATHE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.32x
Industry
4.83x
ATHE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATHE's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ATHE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ATHE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.2M
Liabilities
$1.8M
Debt to equity
0.05
ATHE's short-term assets ($40.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATHE's short-term assets ($40.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATHE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATHE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ATHE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATHE vs Biotech Stocks
Alterity Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.